Early clinical studies to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy volunteers and subjects with type 2 diabetes mellitus

被引：0
|
作者：
Hussey, Elizabeth K.
Clark, Richard V.
Amin, Dipti M.
Kipnes, Mark S.
O'Connor-Semmes, Robin L.
O'Driscoll, Eilis C.
Leong, Jenny
Murray, Sharon C.
Dobbins, Robert L.
Nunez, Derek J.
机构：
来源：
DIABETES | 2007年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A49 / A49
页数：1
相关论文
共 50 条
  • [1] Clinical studies to assess safety, pharmacokinetics and pharmacodynamics of sergliflozin, a novel inhibitor of glucose reabsorption
    Kler, L.
    Hussey, E. K.
    Dobbins, R. L.
    O'Connor-Semmes, R. L.
    Kapur, A.
    Murray, S. C.
    Clark, R. V.
    Stoltz, R. R.
    Stockman, N. L.
    Amin, D. M.
    Kipnes, M. S.
    O'Driscoll, E. C.
    Leong, J.
    Nunez, D. J. R.
    DIABETOLOGIA, 2007, 50 : S376 - S377
  • [2] Single-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus
    Hussey, Elizabeth K.
    Clark, Richard V.
    Amin, Dipti M.
    Kipnes, Mark S.
    O'Connor-Semmes, Robin L.
    O'Driscoll, Eilis C.
    Leong, Jenny
    Murray, Sharon C.
    Dobbins, Robert L.
    Layko, Debbi
    Nunez, Derek J. R.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (06): : 623 - 635
  • [3] A double-blind randomized repeat dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of three times daily dosing of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy overweight and obese subjects
    Hussey, Elizabeth K.
    Dobbins, Robert L.
    Stolz, Randall R.
    Stockman, Nancy L.
    O'Connor-Semmes, Robin L.
    Kapur, Anita
    Murray, Sharon C.
    Nunez, Derek J.
    DIABETES, 2007, 56 : A131 - A131
  • [4] Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers
    Ogata, Koichiro
    Mendell-Harary, Jeanne
    Tachibana, Masaya
    Masumoto, Hiroshi
    Oguma, Toshihiro
    Kojima, Masazumi
    Kunitada, Satoshi
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (07): : 743 - 753
  • [5] Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects
    Sarashina, Akiko
    Koiwai, Kazuki
    Seman, Leo J.
    Yamamura, Norio
    Taniguchi, Atsushi
    Negishi, Takahiro
    Sesoko, Shogo
    Woerle, Hans J.
    Dugi, Klaus A.
    DRUG METABOLISM AND PHARMACOKINETICS, 2013, 28 (03) : 213 - 219
  • [6] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885, a Novel Glycogen Phosphorylase Inhibitor, in Subjects with Type 2 Diabetes Mellitus.
    Lin, J.
    Vasist, L. S.
    Stuart, J. S.
    Byerly, R. L.
    Clark, R. V.
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [7] SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), AND PHARMACODYNAMICS (PD) OF SINGLE DOSES OF TAK-272, A NOVEL RENIN INHIBITOR, IN HEALTHY MALE SUBJECTS
    Matsuno, K.
    Kuroda, S.
    Tanaka, S.
    Nakamichi, H.
    Komura, E.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [8] Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Inhaled Doses of Umeclidinium in Healthy Subjects: Two Randomized Studies
    Anthony Cahn
    Ruth Tal-Singer
    Isabelle J. Pouliquen
    Rashmi Mehta
    Andrew Preece
    Kelly Hardes
    Glenn Crater
    Amanda Deans
    Clinical Drug Investigation, 2013, 33 : 477 - 488
  • [9] Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Inhaled Doses of Umeclidinium in Healthy Subjects: Two Randomized Studies
    Cahn, Anthony
    Tal-Singer, Ruth
    Pouliquen, Isabelle J.
    Mehta, Rashmi
    Preece, Andrew
    Hardes, Kelly
    Crater, Glenn
    Deans, Amanda
    CLINICAL DRUG INVESTIGATION, 2013, 33 (07) : 477 - 488
  • [10] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
    Heise, Tim
    Seman, Leo
    Macha, Sreeraj
    Jones, Peter
    Marquart, Alexandra
    Pinnetti, Sabine
    Woerle, Hans J.
    Dugi, Klaus
    DIABETES THERAPY, 2013, 4 (02) : 331 - 345
12345